Association of B2 Receptor Polymorphisms and ACE Activity With ACE Inhibitor-Induced Angioedema in Black and Mixed-Race South Africans

Journal of Clinical Hypertension

Volumn 15, Issue 6, 2013, Pages 413-419

  Moholisa, Retsilisitsoe R ^a   Rayner, Brian R ^a   Patricia Owen, E ^a   Schwager, Sylva L U ^a   Stark, Joalice S ^a   Badri, Motassim ^a   Cupido, Clint L ^b   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Victoria Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; LISINOPRIL; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ALLELE; ANGIONEUROTIC EDEMA; ARTICLE; CONTROLLED STUDY; COUGHING; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICA; BLOOD; CHEMICALLY INDUCED DISORDER; COMORBIDITY; ETHNOLOGY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; NEGRO; POLYMERASE CHAIN REACTION; BLACK PERSON; CHEMICALLY INDUCED;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; COUGH; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RECEPTOR, BRADYKININ B2; SOUTH AFRICA;

EID: 84878801420     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12104     Document Type: Article

References (33)

1. Blais C Jr, Rouleau JL, Brown NJ, et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology. 1999;43:293-302.
2. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
3. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60:8-13.
4. Kostis JB, Kim HJ, Rusnak J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165:1637-1642.
5. Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51:141-147.
6. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311-317.
7. Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-1697.
8. Molinaro G, Cugno M, Perez M, et al. Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther. 2002;303:232-237.
9. Duan QL, Nikpoor B, Dube MP, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005;77:617-626.
10. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci. 2005;99:6-38.
11. Braun A, Maier E, Kammerer S, et al. A novel sequence polymorphism in the promoter region of the human B2-bradykinin receptor gene. Hum Genet. 1996;97:688-689.
12. Soubrier F, Cambien F. The angiotensin I-converting enzyme gene polymorphism: implication in hypertension and myocardial infarction. Curr Opin Nephrol Hypertens. 1994;3:25-29.
13. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343-1346.
14. Gulec M, Caliskaner Z, Tunca Y, et al. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Allergol Immunopathol (Madr). 2008;36:134-140.
15. Ducroix JP, Outurquin S, Benabes-Jezraoui B, et al. [Angioedema and angiotensin converting enzyme inhibitors: a report of 19 cases]. Rev Med Interne. 2004;25:501-506.
16. Braun A, Kammerer S, Maier E, et al. Polymorphisms in the gene for the human B2-bradykinin receptor. New tools in assessing a genetic risk for bradykinin-associated diseases. Immunopharmacology. 1996;33:32-35.
17. Van Guilder GP, Pretorius M, Luther JM, et al. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension. 2008;51:454-459.
18. Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol. 1997;99:134-146.
19. Gainer JV, Brown NJ, Bachvarova M, et al. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. Am J Hypertens. 2000;13:1268-1273.
20. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. J Hum Hypertens. 2002;16:857-863.
21. Danilov SM, Balyasnikova IV, Albrecht RF, Kost OA. Simultaneous determination of ACE activity with 2 substrates provides information on the status of somatic ACE and allows detection of inhibitors in human blood. J Cardiovasc Pharmacol. 2008;52:90-103.
22. Friedland J, Silverstein E. A sensitive fluorimetric assay for serum angiotensin-converting enzyme. Am J Clin Pathol. 1976;66:416-424.
23. Lieberman J, Sastre A. An angiotensin-converting enzyme (ACE) inhibitor in human serum. Increased sensitivity of the serum ACE assay for detecting active sarcoidosis. Chest. 1986;90:869-875.
24. Benessiano J, Crestani B, Mestari F, et al. High frequency of a deletion polymorphism of the angiotensin-converting enzyme gene in asthma. J Allergy Clin Immunol. 1997;99:53-57.
25. Mehri S, Baudin B, Mahjoub S, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism in a Tunisian healthy and acute myocardial infarction population. Genet Test Mol Biomarkers. 2010;14:85-91.
26. Tsai IJ, Yang YH, Lin YH, et al. Angiotensin-converting enzyme gene polymorphism in children with idiopathic nephrotic syndrome. Am J Nephrol. 2006;26:157-162.
27. Bas M, Hoffmann TK, Tiemann B, et al. Potential genetic risk factors in angiotensin-converting enzyme-inhibitor-induced angio-oedema. Br J Clin Pharmacol. 2010;69:179-186.
28. Dhamrait SS, Payne JR, Li P, et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24:1672-1680.
29. Eyries M, Michaud A, Deinum J, et al. Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region. J Biol Chem. 2001;276:5525-5532.
30. Nesterovitch AB, Hogarth KD, Adarichev VA, et al. Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. PLoS ONE. 2009;4:e8282.
31. Sugimura K, Tian XL, Hoffmann S, et al. Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization. Biochem Biophys Res Commun. 1998;247:466-472.
32. Stephan D, Grima M, Welsch M, et al. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system. Fundam Clin Pharmacol. 1996;10:474-483.
33. Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189-2196.